Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

Erstellt von Cantor Fitzgerald 

Hutchison China MediTech Ltd ADR diskutieren

Hutchison China MediTech Ltd ADR

WKN: A2AF74 / Symbol: HCM / Name: Chi-Med / Aktie / Pharmazeutika / Mid Cap /

13,10 €
-0,76 %

HUTCHMED (China) Limited (NASDAQ: HCM) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
Ratings data for HCM provided by MarketBeat

Einschätzung Buy
Rendite (%) 36,29 %
Kursziel 45,10
Veränderung
Endet am 24.07.24

HUTCHMED (China) Limited (NASDAQ: HCM) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $50.00 price target on the stock.
Ratings data for HCM provided by MarketBeat

Einschätzung Buy
Rendite (%) 14,71 %
Kursziel 46,68
Veränderung
Endet am 05.09.24

HUTCHMED (China) Limited (NASDAQ: HCM) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $50.00 price target on the stock.
Ratings data for HCM provided by MarketBeat

Einschätzung Buy
Rendite (%) -7,34 %
Kursziel 20,23
Veränderung
Endet am 24.11.24

HUTCHMED (China) Limited (NASDAQ: HCM) was upgraded by analysts at Deutsche Bank Aktiengesellschaft from a "hold" rating to a "buy" rating. They now have a $22.10 price target on the stock.
Ratings data for HCM provided by MarketBeat

HUTCHMED (China) Limited (NASDAQ: HCM) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
Ratings data for HCM provided by MarketBeat

HUTCHMED (China) Limited (NASDAQ: HCM) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.
Ratings data for HCM provided by MarketBeat

HUTCHMED (China) Limited (NASDAQ: HCM) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.
Ratings data for HCM provided by MarketBeat

Einschätzung Buy
Rendite (%) -8,22 %
Kursziel 23,95
Veränderung
Endet am 22.07.26

HUTCHMED (China) Limited Sponsored ADR (NASDAQ: HCM) had its price target raised by analysts at Bank of America Corporation from $27.00 to $28.00. They now have a "buy" rating on the stock.
Ratings data for HCM provided by MarketBeat

Einschätzung Sell
Rendite (%) -2,19 %
Kursziel 11,72
Veränderung
Endet am 22.09.26

HUTCHMED (NASDAQ:HCM) was downgraded by analysts at Morgan Stanley from an "equal weight" rating to an "underweight" rating. They now have a $13.75 price target on the stock.
Ratings data for HCM provided by MarketBeat

HUTCHMED (NASDAQ:HCM) was upgraded by analysts at Wall Street Zen from a "hold" rating to a "buy" rating.
Ratings data for HCM provided by MarketBeat